Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Δ-9-tetrahydrocannabinol dose increase leads to warfarin drug interaction and elevated INR.

< BACK TO ARCHIVE


2020 Aug 19


J Am Pharm Assoc (2003)


http://www.ncbi.nlm.nih.gov/pubmed/32828704?dopt=Abstract

Δ-9-tetrahydrocannabinol dose increase leads to warfarin drug interaction and elevated INR.

Authors

Δ-9-tetrahydrocannabinol dose increase leads to warfarin drug interaction and elevated INR.
Brown GW, Bellnier TJ, Janda M, Miskowitz K
J Am Pharm Assoc (2003). 2020 Aug 19.
PMID: 32828704.

Abstract

We have reported a case of a drug-drug interaction (DDI) involving warfarin and Δ-9-tetrahydrocannabinol (THC) that resulted in a supratherapeutic international normalized ratio (INR) level. The purpose of this case report is to highlight the possibility of a pharmacokinetic DDI between THC and warfarin.
Read This Paper